Cassiopea S.p.A. | Mutual Funds
Mutual Funds that own Cassiopea S.p.A.
AMG Substanzwerte Schweiz
276,118
2.76%
24,920
2.39%
12/31/2017
UBS (CH) Institutional Fund - Small & Mid Cap Equities Switzer
79,861
0.8%
-3,769
0.5%
12/29/2017
Adamant Global Biotech
51,823
0.52%
-2,400
2.61%
12/29/2017
New Capital UCITS Fund Plc - Swiss Select Equity Fund
50,000
0.5%
0
1.61%
04/30/2018
T Rowe Price Funds SICAV - European Smaller Companies Equity
41,881
0.42%
7,380
0.81%
06/30/2018
UBS (CH) Equity Fund - Mid Caps Switzerland
39,862
0.4%
0
0.52%
12/29/2017
AMG Europa Infra
36,805
0.37%
0
1.94%
12/31/2017
UBS (CH) Equity Fund - Small Caps Switzerland
33,283
0.33%
0
0.6%
12/29/2017
CSIF Switzerland Total Market Index
31,042
0.31%
57
0.02%
05/31/2018
15,700
0.16%
0
0.02%
12/29/2017
| Address |
Via Cristoforo Colombo, 1
Milan Milan 20020
Italy
|
|
Employees
|
- |
| Website |
http://www.cassiopea.com |
| Updated |
07/08/2019 |
| Cassiopea SpA is a clinical-stage specialty pharmaceutical company. It engages in developing and commercializing and medical dermatology products focusing on the topical treatment of acne, androgenic alopecia, and genital warts. The company products include Winlevi, Breezula, CB-06-02 and CB-06-01. |
